These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 11890474)
1. Strategic importance of research support through pathology. Cockerell GL; McKim JM; Vonderfecht SL Toxicol Pathol; 2002; 30(1):4-7. PubMed ID: 11890474 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Kramer JA; Sagartz JE; Morris DL Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090 [TBL] [Abstract][Full Text] [Related]
4. Toxicogenomics, drug discovery, and the pathologist. Boorman GA; Anderson SP; Casey WM; Brown RH; Crosby LM; Gottschalk K; Easton M; Ni H; Morgan KT Toxicol Pathol; 2002; 30(1):15-27. PubMed ID: 11890469 [TBL] [Abstract][Full Text] [Related]
5. The pathologist and toxicologist in pharmaceutical product discovery. Alden CL; Sagartz JE; Smith PF; Wilson AG; Bunch RT; Morris DL Toxicol Pathol; 1999; 27(1):104-6. PubMed ID: 10367682 [TBL] [Abstract][Full Text] [Related]
6. Toxicologic pathology in the 21st century. Ettlin RA Toxicol Pathol; 2013 Jul; 41(5):689-708. PubMed ID: 23143188 [TBL] [Abstract][Full Text] [Related]
7. [Aiming for zero blindness]. Nakazawa T Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109 [TBL] [Abstract][Full Text] [Related]
8. Alternative strategies in drug development: clinical pharmacological aspects. Kuhlmann J Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949 [TBL] [Abstract][Full Text] [Related]
9. State-of-the-art genomics approaches in toxicology. Van Hummelen P; Sasaki J Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069 [TBL] [Abstract][Full Text] [Related]
10. Drug research: from the idea to the product. Kuhlmann J Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711 [TBL] [Abstract][Full Text] [Related]
12. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Meanwell NA Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149 [TBL] [Abstract][Full Text] [Related]
14. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186 [TBL] [Abstract][Full Text] [Related]
15. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Yang Y; Blomme EA; Waring JF Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262 [TBL] [Abstract][Full Text] [Related]
16. Drug safety testing paradigm, current progress and future challenges: an overview. Ahuja V; Sharma S J Appl Toxicol; 2014 Jun; 34(6):576-94. PubMed ID: 24777877 [TBL] [Abstract][Full Text] [Related]
17. Modern imaging technologies in toxicologic pathology: An overview. Ying X; Monticello TM Toxicol Pathol; 2006; 34(7):815-26. PubMed ID: 17178685 [TBL] [Abstract][Full Text] [Related]
19. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Baillie TA Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955 [TBL] [Abstract][Full Text] [Related]
20. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Amacher DE Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]